Alnylam Pharmaceuticals Inc. (NASDAQ:ALNY) was downgraded by stock analysts at Needham & Company LLC to a “buy” rating in a report issued on Thursday. They presently have a $137.00 price objective on the biopharmaceutical company’s stock. Needham & Company LLC’s price objective would indicate a potential upside of 94.88% from the company’s current price.
Other equities analysts have also issued reports about the stock. Jefferies Group reiterated a “buy” rating and issued a $80.00 target price (down from $119.00) on shares of Alnylam Pharmaceuticals in a report on Wednesday, June 8th. FBR & Co reiterated a “buy” rating on shares of Alnylam Pharmaceuticals in a report on Friday, June 10th. Cowen and Company reiterated a “buy” rating on shares of Alnylam Pharmaceuticals in a report on Sunday, June 12th. Leerink Swann reiterated a “buy” rating on shares of Alnylam Pharmaceuticals in a report on Sunday, June 12th. Finally, Credit Suisse Group AG reiterated a “buy” rating on shares of Alnylam Pharmaceuticals in a report on Sunday, June 12th. Six research analysts have rated the stock with a hold rating and ten have given a buy rating to the company’s stock. The stock has a consensus rating of “Buy” and a consensus price target of $104.07.
Alnylam Pharmaceuticals (NASDAQ:ALNY) opened at 70.30 on Thursday. Alnylam Pharmaceuticals has a one year low of $49.96 and a one year high of $110.75. The company’s 50-day moving average is $72.86 and its 200 day moving average is $66.46. The stock’s market capitalization is $6.03 billion.
Alnylam Pharmaceuticals (NASDAQ:ALNY) last announced its quarterly earnings data on Thursday, August 4th. The biopharmaceutical company reported ($1.05) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.24) by $0.19. Alnylam Pharmaceuticals had a negative net margin of 1,204.91% and a negative return on equity of 29.60%. The company earned $8.70 million during the quarter, compared to analysts’ expectations of $8.09 million. During the same quarter in the prior year, the company earned ($0.85) EPS. Alnylam Pharmaceuticals’s revenue was up .2% compared to the same quarter last year. Equities analysts expect that Alnylam Pharmaceuticals will post ($4.64) EPS for the current year.
In other news, CEO John Maraganore sold 30,151 shares of the company’s stock in a transaction that occurred on Wednesday, July 20th. The shares were sold at an average price of $64.69, for a total value of $1,950,468.19. Following the transaction, the chief executive officer now directly owns 148,465 shares in the company, valued at approximately $9,604,200.85. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. 4.00% of the stock is currently owned by insiders.
A number of large investors have recently added to or reduced their stakes in the company. Slate Path Capital LP raised its stake in Alnylam Pharmaceuticals by 56.6% in the first quarter. Slate Path Capital LP now owns 1,135,000 shares of the biopharmaceutical company’s stock worth $71,244,000 after buying an additional 410,000 shares during the period. State Street Corp raised its stake in Alnylam Pharmaceuticals by 15.7% in the first quarter. State Street Corp now owns 1,936,520 shares of the biopharmaceutical company’s stock worth $121,553,000 after buying an additional 262,783 shares during the period. Bridger Management LLC acquired a new stake in Alnylam Pharmaceuticals during the first quarter worth about $50,041,000. Turner Investments L.P. acquired a new stake in Alnylam Pharmaceuticals during the second quarter worth about $575,000. Finally, Geode Capital Management LLC raised its stake in Alnylam Pharmaceuticals by 7.1% in the first quarter. Geode Capital Management LLC now owns 480,181 shares of the biopharmaceutical company’s stock worth $30,123,000 after buying an additional 31,627 shares during the period. Institutional investors own 85.96% of the company’s stock.
About Alnylam Pharmaceuticals
Alnylam Pharmaceuticals, Inc is a biopharmaceutical company. The Company is engaged in developing therapeutics based on ribonucleic acid (RNA) interference (RNAi). It is focused on the use of its N-acetylgalactosamine (GalNAc)-conjugate strategy for delivery of small interfering RNAs (siRNAs). Its pipeline of investigational RNAi therapeutics focuses in three Strategic Therapeutic Areas (STArs): Genetic Medicines; Cardio-Metabolic Disease, and Hepatic Infectious Disease.
Receive News & Ratings for Alnylam Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alnylam Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.